Appendix 4E and 2021 Annual Report
Filed with ASX · · 80 pages · English
Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $4,062,920 (30 June 2020: $2,748,539). During the period, the Group had total revenue of $1,338,377 (2020: $772,844), consisting of the R&D tax incentive of $1,188,581 (2020: $623,197), licencing income of $27,500 (2020: $27
Story so far
Earlier from Patrys
- Market Update - PAT-DX1 Clinical Trial Preparation
- Appendix 4C - Quarterly - 30 June 2021
- PAT-DX1 Improves Survival in Model of Pancreatic Cancer
- Full size deoxymab PAT-DX3 crosses the blood brain barrier
- Response to ASX Query
Later from Patrys
- PAT-DX3 proof of concept as potential ADC targeting antibody
- Patrys proof of concept ADC significantly increases survival
- Appendix 4C - Quarterly - 30 September 2021
- $7.8M Capital Raising
- Rights Issue Offer Document
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys